Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RSK3 switches cell fate: from stress-induced senescence to malignant progression

ABSTRACT: RSK3 switches cell fate: from stress-induced senescence to malignant progression

PROVIDER: PRJNA1017821 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RSK3 switches cell fate: from stress-induced senescence to malignant progression

Project description:TGFβ signaling induces several cell phenotypes including cellular senescence, a stable form of cell cycle arrest accompanied by a secretory program, and epithelial-mesenchymal transition (EMT) in normal epithelial cells. During carcinogenesis cells lose the ability to undergo senescence in response to TGFβ but they maintain an EMT, which can contribute to tumor progression and resistance. A screen with active kinases in HMECs upon TGFβ treatment identified that the serine threonine kinase RSK3, or RPS6KA2, reverted TGFβ-induced senescence. Interestingly, RSK3 expression decreased in response to TGFβ in a SMAD3-dependent manner, and its constitutive expression rescued SMAD3-induced premature senescence, indicating that decrease of RSK3 itself contributes to TGFβ-induced senescence. Mechanistically, using transcriptomic analyses and affinity purification coupled to mass spectrometry-based proteomics, we unveiled that RSK3 regulates senescence by inhibiting NF-κΒ pathway through the decrease in proteasome-mediated IκBα degradation. Strikingly, senescent TGFβ-treated HMEC display features of epithelial to mesenchymal transition (EMT) and during RSK3-induced senescence escape HMEC conserve EMT features. Importantly, RSK3 expression correlates with EMT and invasion, and anti-correlates with senescence and NF-κΒ in human claudin-low breast tumors and its expression accelerates formation of breast invasive tumors in the mouse mammary gland. We conclude that RSK3 switches cell fate from senescence to malignancy in response to TGFβ signals.

2023-10-01 | GSE243320 | GEO

Modeling Malignant Progression in Glioma

Project description:Modeling Malignant Progression in Glioma

| PRJNA762124 | ENA

Modeling Malignant Progression in Glioma

Project description:Modeling Malignant Progression in Glioma

| PRJNA767071 | ENA

Modeling Malignant Progression in Glioma

Project description:Modeling Malignant Progression in Glioma

| PRJNA762123 | ENA

Sirt6 attenuates chondrocyte senescence and osteoarthritis progression

Project description:Sirt6 attenuates chondrocyte senescence and osteoarthritis progression

| PRJNA851254 | ENA

TRIM15 drives chondrocyte senescence and osteoarthritis progression

Project description:TRIM15 drives chondrocyte senescence and osteoarthritis progression

| PRJNA1184794 | ENA

SRC skews cell fate from apoptosis to senescence

Project description:SRC skews cell fate from apoptosis to senescence

| PRJNA714948 | ENA

Sirt6 attenuates chondrocyte senescence and osteoarthritis progression

Project description:Sirt6 attenuates chondrocyte senescence and osteoarthritis progression

2022-11-29 | GSE206513 | GEO

CD146 accelerates malignant progression of phyllodes tumor cells

Project description:CD146 accelerates malignant progression of phyllodes tumor cells

| PRJNA944931 | ENA

CD146 accelerates malignant progression of phyllodes tumor cells

Project description:Breast malignant phyllodes tumors (PTs) are rapid-progressing tumors, known to lack effective treatment and suitable prognostic markers as well as elaborate studies. Herein,we found that level of CD146 is progressively elevated with malignant progression of PTs and is an independent predictor for prognosis of PT patients.Mechanistically, CD146 activates the PI3K/AKT signaling pathway, thereby enhancing malignant behaviors of PT cells.This study unveils a CD146-PI3K/AKT axis in modulating the malignant progression of PTs, and open avenues to develop a novel target for precise prognosis and treatment for breast malignant PTs.

2023-12-01 | GSE227380 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data